Cannabis Genotyping Pipeline

绿道温室大麻公司（绿道）是一家垂直整合的药用大麻 ** 生产商，最近从其母公司Sunrite Greenhouses Ltd.分拆出来，该公司在商业园艺方面拥有超过45年的经验，拥有超过400万平方英尺的水培生产面积（50万平方米）。英尺这是专门为绿道）。绿道还可以获得各种独特的种质 **（即种子和组织）资源，包括一位育种专家以种子形式合法赠送的100种高价值大麻品种。虽然绿道拥有丰富的园艺专业知识和基础设施，但它缺乏遗传学研究能力，因此寻求学术合作伙伴合作开发一种新的快速系统，用于遗传学表征其种质。这将使绿道能够合理地选择其菌株的一个子集，用于进一步的开发、育种和商业化。这也将为关键性状的遗传作图、品种保护和质量保证奠定基础。为了实现开发一种快速的，基于DNA的方法来定义大麻菌株的相关性的合作目标，我们将利用公共领域中已经存在的1300种大麻菌株的DNA序列信息，并确定一组384个遗传标记（SNP，单核苷酸多态性），这些标记将用于基因分型测序分析，以产生每个菌株的遗传指纹。将从100个高价值菌株和已知菌株中获得这些遗传 ** 指纹，以鉴定 ** 相关种质的集群。这些聚类也将与收集到的关于每种菌株的生长和（在未来）化学特性的信息进行比较。将 ** 确定信息标记的最小数量，以便将来进一步简化方案。这些结果将成为未来 ** 合作的基础，包括开发多样化的育种和绘图种群。

Greenway Greenhouse Cannabis Corporation (Greenway) is a vertically integrated medicinal cannabis**producer, recently spun off from its parent company, Sunrite Greenhouses Ltd., which has over 45 years of**experience in commercial horticulture and over 4 million square feet of hydroponic production area (0.5**million sq. ft. of this is dedicated to Greenway). Greenway also has access to diverse and unique germplasm**(i.e. seed and tissue) resources, including a collection of 100 high-value cannabis strains gifted legally as seeds**by an expert breeder. Although Greenway has substantial horticultural expertise and infrastructure, it lacks**research capacity in genetics and therefore seeks an academic partner to collaborate on development of a novel,**rapid system for genetically characterizing its germplasm. This will allow Greenway to rationally select a**subset of its strains for further development, breeding, and commercialization. This will also lay a foundation**for genetic mapping of key traits, variety protection, and quality assurance.**To accomplish the collaborative objective of developing a rapid, DNA-based method for defining the**relatedness of cannabis strains, we will leverage DNA sequence information already in the public domain for**1300 cannabis strains, and identify a set of 384 genetic markers (SNPs, single-nucleotide polymorphisms) that**will be used in a genotyping-by-sequencing assay to produce genetic fingerprints for each strain. These genetic**fingerprints will be obtained for the 100 high-value strains and from known strains, to identify clusters of**related germplasm. These clusters will also be compared to information collected about the growth and (in the**future) the chemical properties of each strain. The minimum number of informative markers will be**determined to further streamline the protocol in the future. These results will form the basis of future**collaborations including development of diverse breeding and mapping populations.